Open access
Aug 2026
Combined type 2 cytokine blockade enhances PD-1-mediated antitumor immunity.
Immune checkpoint inhibitors improve outcomes for many patients with cancer, but resistance remains a major clinical challenge. Type 2 cytokines, including IL-4, IL-13, and thymic stromal lymphopoietin (TSLP), have been implicated in suppressing anti-tumor immunity. Here, we investigated whether combined blockade of IL...
T. Fabre, Eleanore Hendrickson, K. McGourty et al.
· Cell Reports · 0 citations